National Postdoctoral Association

Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Drug development, Therapy, Headache, Plasma, Large-cell lung carcinoma, WHO, Transducin, AML, Texas Children's Hospital, Growth, RECIST, Adult, MTD, ALT, Infrared spectroscopy correlation table, AACR, Research, Doctor of Philosophy, Hospital, CDT, Metastasis, Neoplasm, Stomatitis, Trae Elston, American Association, CEO, Poster, Osteosarcoma, OS, MD, Index (publishing), Association, Safety, DLT, National Postdoctoral Association, Plantar fibromatosis, Cell membrane, Hypophosphatemia, Disease, Toxicity, Pharmaceutical industry, Medical imaging, Patient

HOUSTON, April 8, 2022 /PRNewswire/ -- Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that three posters involving research into tegavivint will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including initial results from a Phase 1 study of tegavivint in patients with desmoid sarcomas. AACR 2022 is being held April 8-13, 2022, in New Orleans.

Key Points: 
  • AACR 2022 is being held April 8-13, 2022, in New Orleans.
  • The poster details results from the dose-escalation portion of a Phase 1 trial of tegavivint in adult patients with progressive, unresectable desmoid sarcoma.
  • Research demonstrating potent anti-tumor activity in a broad range of pre-clinical models indicate that tegavivint has the potential for clinical utility in multiple cancer types.
  • Iterion is the recipient of an up to$15.9 millionProduct Development Award from the Cancer Prevention and Research Institute ofTexas (CPRIT).For more information on Iterion, please visit https://iteriontherapeutics.com .

Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, September 30, 2021
STRI, Therapy, University of California, San Francisco, RNA transfection, Molecular biology, Research, Time, American Association, Protein, Symposium, National Postdoctoral Association, Conference, NASDAQ, Patient, Molecule, AACR, ER, Baylor College of Medicine, Treatment, San Francisco, NSCLC, 4F, University, American Association for Cancer Research, EIF4A, MNK, SAN, Medicine, National Cancer Institute, EIF4E, COVID-19, Pfizer, EORTC, Drug development, European Organization for Quality, DARPA, Survival, National, NCI, KRAS, Escape Room, Pembrolizumab, Stri, GLOBE, Department, Pharmaceutical industry

ET October 10 at 5:45 pm ET

Key Points: 
  • ET October 10 at 5:45 pm ET
    Hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2021 Molecular Targets and Cancer Therapeutics conference will take place as a virtual eventOctober 7-10, 2021.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.